RICHMOND, Va. (WRIC) — Virginia Commonwealth University’s (VCU) Massey Comprehensive Cancer Center is the first and only authorized treatment center in the commonwealth to offer a special type of therapy for patients in advanced stages of melanoma.
Tumor-infiltrating lymphocyte (TIL) therapy, is a highly personalized treatment that uses the tumor tissue within a patient to create individualized immune cells by the billions — which are then put back into the patient to fight the disease, according to a release.
This is the first FDA-approved cellular therapy for solid tumors, and is also referred to as adoptive cell therapy, Amtagvi or lifileucel…